FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Taconic Capital Advisors LP

2. Date of Event Requiring Statement (MM/DD/YYYY)
6/27/2010 

3. Issuer Name and Ticker or Trading Symbol

Molecular Insight Pharmaceuticals, Inc. [MIPI]

(Last)        (First)        (Middle)

450 PARK AVENUE, 9TH FLOOR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
_____ Officer (give title below)          ___ X ___ Other (specify below)
/ Reference Footnote 1

(Street)

NEW YORK, NY 10022       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.01 per share   0   (1) I   See Footnote   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant for Common Stock   11/16/2007   11/16/2012   Common Stock, par value $0.01 per share   762691   $5.87   I   See Footnotes   (2) (3) (4)

Explanation of Responses:
( 1)  Not Applicable as Reporting Persons do not beneficially own any non-derivative securities of the Issuer. See Footnotes 2, 3 and 4.
( 2)  The Reporting Persons may be deemed to be a member of a "group" with certain other holders of equity securities and/or derivative securities of the Issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. If such a group were determined to exist, the members hold in the aggregate more than ten percent (10%) of the Issuer's equity securities. Each of the Reporting Persons disclaims the existence of such a group and disclaims beneficial ownership of any of the securities and/or derivative securities of the Issuer to which this Form 3 relates for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of such Reporting Person's pecuniary interest in the securities.
( 3)  This Form 3 relates to the securities held for the account of the Taconic Opportunity Fund L.P. ("Taconic Opportunity Fund"). Taconic Capital Advisors L.P. ("Taconic Advisors") and Taconic Capital Advisors UK LLP ("Taconic Advisors UK") serve as the investment managers to the Taconic Opportunity Fund. Taconic Capital Performance Partners LLC ("Taconic Partners") serves as the general partner to Taconic Advisors. Taconic Associates LLC ("Taconic Associates") serves as the general partner to the Taconic Opportunity Fund.
( 4)  Mr. Brody is a principal of Taconic Advisors, a director of Taconic Capital Services UK Ltd., the managing member of Taconic Advisors UK, and a manager of Taconic Partners and Taconic Associates. Mr. Brosens is a principal of Taconic Advisors, a director of Taconic Capital Services UK Ltd., the manager member of Taconic Advisors UK, and a manager of Taconic Partners and Taconic Associates. As such, Taconic Advisors, Taconic Advisors UK, Taconic Associates, Mr. Brody, and Mr. Brosens may be deemed to have voting and dispositive power over the securities held for the account of the Taconic Opportunity Fund.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Taconic Capital Advisors LP
450 PARK AVENUE
9TH FLOOR
NEW YORK, NY 10022



Reference Footnote 1
Taconic Associates LLC
450 PARK AVENUE, 9TH FLOOR
NEW YORK, NY 10022



Reference Footnote 1
Taconic Capital Advisors UK LLP
450 PARK AVENUE
9TH FLOOR
NEW YORK, NY 10022



Reference Footnote 1
BRODY KENNETH D
450 PARK AVENUE
9TH FLOOR
NEW YORK, NY 10022



Reference Footnote 1
BROSENS FRANK
450 PARK AVENUE
9TH FLOOR
NEW YORK, NY 10022



Reference footnote 1

Signatures
TACONIC CAPITAL ADVISORS L.P. By: /s/ Kenneth D. Brody 7/1/2010
** Signature of Reporting Person Date

TACONIC CAPITAL ADVISORS UK LLP By: /s/ Kenneth D. Brody 7/1/2010
** Signature of Reporting Person Date

TACONIC ASSOCIATES LLC By: /s/ Kenneth D. Brody 7/1/2010
** Signature of Reporting Person Date

KENNETH D. BRODY By: /s/ Kenneth D. Brody 7/1/2010
** Signature of Reporting Person Date

FRANK P. BROSENS By: /s/ Frank P. Brosens 7/1/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Molecular Insight Pharmaceuticals (MM) Charts.
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Molecular Insight Pharmaceuticals (MM) Charts.